Please assess the completion status of the following clinical trial:

Trial Title: The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. LDL cholesterol level between 115-190 mg/dL;~2. Able to fast prior to blood draw;~3. Able to comfortably read and write in Chinese;~4. Able and willing to refrain from donating whole blood during study participation;~5. Willing to abstain from consuming large amounts of grapefruit juice.~Exclusion Criteria:~1. Current use of lipid-lowering medications;~2. Documented cardiovascular disease (CVD) by invasive or non-invasive testing (such as coronary angiography, nuclear imaging, stress echocardiography, carotid plaque on ultrasound), previous myocardial infarction (MI), acute coronary syndrome (ACS), coronary revascularization \[percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)\] and other arterial revascularization procedures, ischaemic stroke, peripheral arterial disease(PAD);~3. Patients with type 2 diabetes, patients with type 1 diabetes with target organ damage (such as microalbuminuria);~4. Patients with moderate to severe chronic kidney disease \[glomerular filtration rate (GFR) \< 60 mL/min/1.73㎡\];~5. Markedly elevated single risk factors such as familial dyslipidaemias and severe hypertension;~6. A calculated SCORE ≥5% for 10 year risk of fatal CVD;~7. Cancer;~8. HIV infected;~9. Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis);~10. Active liver disease or unexplained persistent elevated transaminase levels；~11. Major surgery or hospitalization in the 3 months prior to study entry;~12. Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any azole antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors;~13. Female of childbearing potential;~14. Current participation in another clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- XueZhiKang (Type: EXPERIMENTAL): Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
- Simvastatin (Type: ACTIVE_COMPARATOR): Participants will receive 20mg of simvastatin daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).